Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

270
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

692
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
692
Dementia01:30

Dementia

183
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
183
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

738
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
738
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

399
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
399
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

324
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
324

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

Nature communications·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

[Digital transformation in multiple sclerosis: Advances in diagnostics, monitoring and patient-centred care].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Dementia with Lewy bodies].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Impact of the PEPP reimbursement system and other developments on inpatient care of general psychiatry patients 2005 to 2022: a retrospective analysis].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[The pathology of the brain eating amoeba Naegleria fowleri].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Chronic vestibular syndromes: Correct diagnosis and treatment].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Lithium: A "Never‑Ending Story" - Now for Dementia Prevention?]

Fortschritte der Neurologie-Psychiatrie·2026
See all related articles

Related Experiment Video

Updated: Sep 22, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

375

[Therapy Developments in Alzheimer's Disease].

Timo Grimmer1

  • 1Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, München, Germany.

Fortschritte Der Neurologie-Psychiatrie
|May 19, 2022
PubMed
Summary
This summary is machine-generated.

Developing new Alzheimer

More Related Videos

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

1.3K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.4K

Related Experiment Videos

Last Updated: Sep 22, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

375
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

1.3K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Discovery

Background:

  • Alzheimer's disease (AD) drug discovery focuses on symptomatic treatments and disease-modifying therapies.
  • Early detection in pre-dementia and asymptomatic stages is crucial for intervention.
  • Current treatments offer limited symptomatic relief, with no drugs yet approved to halt AD progression in Germany.

Purpose of the Study:

  • To review the current landscape of Alzheimer's disease therapeutics.
  • To highlight the potential and challenges of emerging treatments, particularly anti-amyloid therapies.
  • To emphasize the importance of clinical trial participation for future drug development.

Main Methods:

  • Review of current Alzheimer's disease research and drug development.
  • Analysis of passive immunization strategies using monoclonal antibodies against Aβ42.
  • Discussion of the status of aducanumab approval and its implications.

Main Results:

  • Passive immunization with anti-Aβ42 antibodies shows promise but has faced challenges in pivotal trials.
  • Aducanumab received conditional approval in the US based on amyloid reduction, with ongoing European review.
  • Existing pharmacological treatments provide minimal symptomatic benefit for Alzheimer's disease.

Conclusions:

  • Significant unmet need exists for effective Alzheimer's disease treatments that slow progression.
  • Clinical trials are essential for advancing the development of novel, more effective therapies.
  • Encouraging patient participation in trials, especially in early disease stages, is vital for future breakthroughs.